In view of these findings, it may be relevant to determine whether the MYChigh/METhigh group of HCC patients could especially benefit from the use of combination therapies to boost the response rate to immunotherapy with anti-CTLA4 and/or anti-PD-L1 treatments. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.